At the recent presentation, I thought the most interesting bit of info was Pucci insisting that ARQL could go from expanded Phase I studies with 092 and 087 right into registration trials.
I still hold out hope for Tivantinib in 2nd line HCC. If successful there, then there is the possibility of going to first-line in combo with Nexavar.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.